Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Asthma: Pathogenesis and Management

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Rezafungin Versus Caspofungin in Candidaemia and Invasive Candidiasis: A Post Hoc Pooled Analysis of Phase 2 and Phase 3 Trials.

Mycoses·2026

Same author

Genetic and transcriptomic determinants of disseminated coccidioidomycosis identify a founder variant in <i>NLRX1</i> and ancestry-specific rare variants in immune response genes.

medRxiv : the preprint server for health sciences·2026

Same author

Anti-infective therapy and novel treatment options for coccidioidomycosis.

Expert review of anti-infective therapy·2026

Same author

Sustained Reduction in Cardiopulmonary Fitness in Long COVID: A Report from the RECOVER-adult Cohort Study.

JACC. Advances·2026

Same author

Erratum for Wiederhold et al., "The next-generation polyene EL219 is efficacious in an experimental model of central nervous system coccidioidomycosis caused by <i>Coccidioides immitis</i>".

Antimicrobial agents and chemotherapy·2026

Same author

Exhausted T cell phenotypes in disseminated coccidioidomycosis.

JCI insight·2026

Search research articles

Related Experiment Video

Updated: May 26, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

Pulmonary aspergillosis: recent advances.

George R Thompson¹, Thomas F Patterson

¹Department of Medical Microbiology and Immunology, University of California-Davis, Davis, California, USA. grthompson@ucdavis.edu

Seminars in Respiratory and Critical Care Medicine

|December 15, 2011

Summary

Aspergillosis, a serious fungal infection, presents diverse disease forms. Early diagnosis and antifungal treatments like voriconazole are crucial, with combination therapy showing promise for invasive cases.

More Related Videos

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Published on: March 22, 2012

Related Experiment Videos

Last Updated: May 26, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology

Published on: March 22, 2012

Area of Science:

Medical Mycology
Infectious Diseases
Pulmonology

Background:

Aspergillosis significantly contributes to patient morbidity and mortality.
Disease presentation varies from noninvasive allergic bronchopulmonary aspergillosis (ABPA) to invasive pulmonary aspergillosis in immunocompromised individuals.
Advances in diagnostics and antifungal agents have improved treatment outcomes.

Purpose of the Study:

To review the current landscape of aspergillosis diagnosis and treatment.
To highlight the role of voriconazole and emerging combination therapies.
To discuss the potential impact of host genetics on therapeutic strategies.

Main Methods:

Literature review of diagnostic advancements.
Analysis of current antifungal treatment options, including voriconazole.
Discussion of emerging therapeutic strategies and host genetic factors.

Main Results:

Noninvasive diagnostics expedite antifungal therapy initiation.
Voriconazole is the preferred treatment for invasive pulmonary aspergillosis.
Combination therapy is gaining interest for severe infections.

Conclusions:

Effective management of aspergillosis relies on timely diagnosis and appropriate antifungal selection.
Future treatment strategies may incorporate host genetic information for personalized prophylaxis and therapy.